Our data showed that CREB3L4 could significantly decrease the chemosensitivity of HCC to sorafenib, which was featured by significant decrease in the tumor volume and tumor weight in the shCREB3L4-Sorafenib group compared with the other three groups, especially the shNC-Sorafenib group (all p < 0.05, Figure 6E). This evidence concerns the gene CREB3L4 and hepatocellular carcinoma.